Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Chi

Showing results (311-320 of 410) with videos related to

Pageof 41
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2023
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate CancerKim N Chi, Dana Rathkopf, Matthew R Smith, et al.
Future Oncology (London, England)|December 21, 2023
Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN studySimon Chowdhury, Anders Bjartell, Neeraj Agarwal, et al.
The New England Journal of Medicine|June 1, 2019
Apalutamide for Metastatic, Castration-Sensitive Prostate CancerKim N Chi, Neeraj Agarwal, Anders Bjartell, et al.
The New England Journal of Medicine|August 17, 2012
Increased survival with enzalutamide in prostate cancer after chemotherapyHoward I Scher, Karim Fizazi, Fred Saad, et al.
British Journal of Cancer|November 11, 2023
Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTANJohn Shen, Simon Chowdhury, Neeraj Agarwal, et al.
Future Oncology (London, England)|March 31, 2025
A plain language summary of the results from the MAGNITUDE study assessing how effective and how safe niraparib and abiraterone acetate with prednisone is in patients with metastatic castration-resistant prostate cancerKim N Chi, Dana Rathkopf, Matthew R Smith, et al.
JAMA Network Open|August 20, 2025
Statin Use in Patients With Advanced Prostate Cancer in the TITAN and SPARTAN TrialsSoumyajit Roy, Zeynep Irem Ozay, Avirup Guha, et al.
JNCI Cancer Spectrum|May 6, 2020
Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With DocetaxelSusan Halabi, Sandipan Dutta, Catherine M Tangen, et al.
European Journal of Cancer (Oxford, England : 1990)|May 14, 2022
Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302Brooke E Wilson, Andrew J Armstrong, Johann de Bono, et al.
European Urology Oncology|May 18, 2019
Consensus Statement on Circulating Biomarkers for Advanced Prostate CancerSemini Sumanasuriya, Aurelius Omlin, Andrew Armstrong, et al.
Pageof 41

Showing results (311-320 of 410) with videos related to

Sort By:
Pageof 41
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2023
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate CancerKim N Chi, Dana Rathkopf, Matthew R Smith, et al.
Future Oncology (London, England)|December 21, 2023
Prostate-specific antigen (PSA) decline with apalutamide therapy is associated with longer survival and improved outcomes in individuals with metastatic prostate cancer: a plain language summary of the TITAN studySimon Chowdhury, Anders Bjartell, Neeraj Agarwal, et al.
The New England Journal of Medicine|June 1, 2019
Apalutamide for Metastatic, Castration-Sensitive Prostate CancerKim N Chi, Neeraj Agarwal, Anders Bjartell, et al.
The New England Journal of Medicine|August 17, 2012
Increased survival with enzalutamide in prostate cancer after chemotherapyHoward I Scher, Karim Fizazi, Fred Saad, et al.
British Journal of Cancer|November 11, 2023
Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTANJohn Shen, Simon Chowdhury, Neeraj Agarwal, et al.
Future Oncology (London, England)|March 31, 2025
A plain language summary of the results from the MAGNITUDE study assessing how effective and how safe niraparib and abiraterone acetate with prednisone is in patients with metastatic castration-resistant prostate cancerKim N Chi, Dana Rathkopf, Matthew R Smith, et al.
JAMA Network Open|August 20, 2025
Statin Use in Patients With Advanced Prostate Cancer in the TITAN and SPARTAN TrialsSoumyajit Roy, Zeynep Irem Ozay, Avirup Guha, et al.
JNCI Cancer Spectrum|May 6, 2020
Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With DocetaxelSusan Halabi, Sandipan Dutta, Catherine M Tangen, et al.
European Journal of Cancer (Oxford, England : 1990)|May 14, 2022
Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302Brooke E Wilson, Andrew J Armstrong, Johann de Bono, et al.
European Urology Oncology|May 18, 2019
Consensus Statement on Circulating Biomarkers for Advanced Prostate CancerSemini Sumanasuriya, Aurelius Omlin, Andrew Armstrong, et al.
Pageof 41